Member Info for Taff8

Prims results out Monday, expect updates in it

Expect update in it

Yes just exited about sym, very cheap wouldn't want others to lose out on the big ride.

Coronavirus COVID-19 has focused the minds of governments and businesses worldwide as they seek to minimise risks to public health. The Daily Telegraph published the article "Doorknobs and bells are likely spots for harbouring germs" on 7 March which stated that "Coughs and sneezes undoubtedly spread diseases, but … surface contamination has been found to be more significant than first thought, with some infectious agents surviving in hospitals for 46 months." The article said that, according to the Greifswald University Hospital in Germany viruses could survive on plastics for up to nine days at room temperature.

Coronavirus COVID-19 has focused the minds of governments and businesses worldwide as they seek to minimise risks to public health. The Daily Telegraph published the article "Doorknobs and bells are likely spots for harbouring germs" on 7 March which stated that "Coughs and sneezes undoubtedly spread diseases, but … surface contamination has been found to be more significant than first thought, with some infectious agents surviving in hospitals for 46 months." The article said that, according to the Greifswald University Hospital in Germany viruses could survive on plastics for up to nine days at room temperature.

Coronavirus COVID-19 has focused the minds of governments and businesses worldwide as they seek to minimise risks to public health. The Daily Telegraph published the article "Doorknobs and bells are likely spots for harbouring germs" on 7 March which stated that "Coughs and sneezes undoubtedly spread diseases, but … surface contamination has been found to be more significant than first thought, with some infectious agents surviving in hospitals for 46 months." The article said that, according to the Greifswald University Hospital in Germany viruses could survive on plastics for up to nine days at room temperature.

Remarkable the mkt cap is only £26m,given the current situation and trumps tweet should be in double figures for sure

Wouldn't want to be out Monday morning, any mention of any deal or solution to corona19 and this will multibag

cevatlon
@cevatlon
·
30s
expecting some positive #sym Preliminary Results on/around 16.03.2020,
also update;
if the specimen is available for tests by an independent laboratory to determine whether they are also effective against viruses, and tests will be run on the COVID-19 virus

Want 16.1

But at 15.5 never mind gonna blow soon

Won't let me buy ffs

· At 30 June 2019, 43 confirmed virus-positive patients had been dosed. At 27 September 2019, this had increased to 55 patients and we now have over 200 patients who have passed screening and are in the pool waiting to develop cold/flu symptoms and provide the remaining 65 dosed patients to meet our target of 120. The trial is expected to complete dosing in Q1 2020, with results available in Q2

London South East
Share PricesSynairgen Share PriceSynairgen Regulatory NewsPhase II Biomarker Data for SNG001 to be presented
Pin to quick picksSynairgen Regulatory News (SNG)
SNG Share Price
SNG Share
Price
SNG Share News
SNG Share
News
SNG Share Chat
SNG Share
Chat
27
SNG Share Trades
SNG Share
Trades
64
SNG Live RNS
SNG
Live RNS
SNG Information Buy SNG SharesBuy SNG SharesAdd SNG to WatchlistAdd SNG to WatchlistAdd SNG to AlertAdd SNG to AlertAdd SNG to myTerminalAdd SNG to myTerminal
Share Price Information for Synairgen (SNG)
London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
26.20
Bid:
26.00
Ask:
26.40
Change:
4.90 (23.00%)
Spread: 0.400 (1.53%)Open: 21.50High: 27.50Low: 21.00Yest. Close: 21.30
SNG Live PriceLast checked at 10:42:40
Phase II Biomarker Data for SNG001 to be presented
Fri, 27th Sep 2019 07:00

RNS Number : 8778N
Synairgen plc
27 September 2019









RNS REACH

Press release

Synairgen plc

('Synairgen' or the 'Company')



Synairgen to Present Phase II Biomarker Data for SNG001 at the European Respiratory Society International Congress



Southampton, UK - 27 September 2019: Synairgen (LSE: SNG), the respiratory drug discovery and development company, is presenting biomarker data from the first part of its ongoing Phase II trial of its wholly-owned antiviral therapy inhaled interferon beta (IFN-beta) in patients suffering from chronic obstructive pulmonary disease (COPD), at the European Respiratory Society (ERS) International Congress being held in Madrid 28 September - 2 October 2019.



Exacerbations of COPD are associated with disease progression and are a major cause of the healthcare burden associated with this common disease. A significant proportion of exacerbations are caused by respiratory viruses, such as those that cause the common cold and flu, when infections spread to the lungs.



Synairgen's two-part Phase II trial, called SG015, has been designed to assess Synairgen's inhaled IFN-beta in COPD patients when they have a cold or flu infection. The data being presented are from Part 1 of the study, in which patients were treated with inhaled IFN-beta when they did not have a cold or flu infection. Analysis of samples from the lung shows that treatment with IFN-beta boosted the lungs' antiviral defences, increasing Synairgen's confidence in the likelihood of a positive outcome in Part 2 of the study in which inhaled IFN-beta is being assessed when patients do have a confirmed respiratory virus infection.



The data will be presented by Synairgen's Chief Scientific Officer, Dr Phillip Monk, at the Congress on Sunday 29 September in the session entitled "COPD clinical trials: new molecules and novel insights" (8.30 to 10.30 am Room 6F).



Professor Tom Wilkinson, leading international lung disease specialist and Chief Investigator for the SG015 study, commented: "Respiratory

Nt 29p to buy there desperate for stock

Shake but can't buy

Investors starting to. Realise sng product

Biotechnology company Tiziana Life Sciences said it was speeding up the development of a treatment for the novel coronavirus.

The company said it was expediating the development of TZLS-501, a monoclonal antibody that could help patients with severe lung damage.

Tiziana said it planned to administer TZLS-501 'using a proprietary formulation technology'.

It had in 2017 entered into a worldwide license for composition-of-matter of TZLS-501 with Swiss company Novimmune.

At 9:11am: (LON:TILS) Tiziana Life Sciences Plc share price was +80.5p at 112.5p

120 to buy

We're not talking about few quid per jab here £££thousands